GALLIUM研究中一线免疫化疗后未达完全代谢缓解的滤泡性淋巴瘤患者PET/CT再评估分析
该分析对GALLIUM试验中一线免疫化疗后经独立评审委员会判定未达完全代谢缓解的54例高肿瘤负荷滤泡性淋巴瘤患者PET/CT进行两位国际专家再阅片。再评估后6例改判为完全代谢缓解,部分患者因炎症或偶发肿瘤所致摄取被重新归类;孤立性肠系膜高代谢常见且多为假阳性。作者建议定量评估确认视觉印象,孤立性肠系膜摄取不伴CT可测量病灶或临床怀疑时无需改变管理。
要点
- 肠系膜高代谢见于20例非完全代谢缓解者,其中14例其他部位均达完全代谢缓解。
- 孤立肠系膜摄取者24个月内进展或死亡3/14(21%),合并其他部位摄取者4/6(67%)。
核心结论
- 诱导免疫化疗后部分患者因炎症或偶发肿瘤所致18F-FDG摄取而被再评估为完全代谢缓解。
- 建议定量评估以确认病灶残留摄取的视觉印象。
- 孤立性肠系膜18F-FDG摄取可能是诱导结束时的常见假阳性,除非增强CT有可测量病灶或临床怀疑活动性疾病,否则不改变临床管理或疾病监测。
研究设计与样本
- GALLIUM试验(NCT01332968)PET子研究的事后分析,纳入一线治疗高肿瘤负荷滤泡性淋巴瘤患者。
- 由两位国际专家对独立评审委员会判定未达完全代谢缓解者的PET/CT进行再阅片,评审委员对其他委员会结果设盲。
- 排除诱导结束时增强CT已显示进展性疾病者,共再评估54例。
主要发现
- 再评估后6例为完全代谢缓解,37例为部分代谢缓解,2例无代谢缓解,9例为进展性代谢疾病。
- 6例改判为完全代谢缓解者中,2例因18F-FDG摄取考虑为炎症,2例考虑为偶发肿瘤,2例视觉接近肝摄取但定量更低。
- Deauville评分5分者较4分者无进展生存和至下次治疗时间有缩短趋势。
- 诱导结束时肠系膜高代谢常见,见于20例非完全代谢缓解者,其中14例其他所有部位均达完全代谢缓解。
- 孤立性肠系膜摄取者24个月内进展或死亡3/14(21%),肠系膜合并其他18F-FDG高摄取部位者4/6(67%)。
临床怎么用
- 作者建议采用定量评估确认病灶残留摄取的视觉印象。
- 作者认为孤立性肠系膜18F-FDG摄取可能是诱导结束时的常见假阳性,除非增强CT有可测量病灶或临床怀疑活动性疾病,否则不改变临床管理或疾病监测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Complete metabolic response (CMR) on PET/CT was the sole independent predictor of overall survival in the PET substudy of the phase III GALLIUM trial (NCT01332968) in first-line treatment of high-tumor-burden follicular lymphoma. The aim of this analysis was to further investigate the outcome of patients not achieving CMR. Methods: Two international experts rereviewed PET/CT scans from patients failing to achieve CMR assessed by the Independent Review Committee masked otherwise to committee results. Metabolic response category and Deauville score were assigned. Progression-free survival (PFS) was investigator-assessed with contrast-enhanced CT. Kaplan-Meier methodology was used to estimate landmark PFS and time to next treatment from end of induction by Deauville score. Patients who experienced CT-based progressive disease at the end of induction were excluded. Results: Fifty-four patients were reviewed. Six had CMR, 37 had a partial metabolic response, 2 had no metabolic response, and 9 had progressive metabolic disease. Patients were reassigned to CMR because 18F-FDG uptake was considered inflammatory (n = 2), was considered incidental neoplasia (n = 2), or was visually close to liver uptake but quantitatively lower (n = 2). There was a trend for shorter PFS and time to next treatment for patients with a Deauville score of 5 than a score of 4. High-grade mesenteric uptake at the end of induction was common, occurring in 20 patients with non-CMR, 14 of whom achieved CMR at all other sites. Only 3 of 14 (21%) patients with mesenteric uptake as the only site of disease experienced progression or death within 24 mo, whereas 4 of 6 patients (67%) with mesenteric and additional sites of 18F-FDG-avid disease experienced progression or death within 24 mo. All patients with early progression had measurable disease on contrast-enhanced CT at 18F-FDG-avid sites at the end of induction. Conclusion: After induction immunochemotherapy, CMR was assigned after reassessment in some patients, in whom increased 18F-FDG uptake was considered due to inflammation or incidental neoplasia rather than to lymphoma. Quantitative assessment to confirm the visual impression of residual uptake in lesions is suggested. Isolated mesenteric 18F-FDG uptake is likely a common false-positive finding at the end of induction and does not warrant changes in clinical management or disease surveillance unless there is measurable disease on contrast-enhanced CT or clinical suspicion of active disease.
引用
- Barrington SF, Mir F, El-Galaly TC, et al. Follicular Lymphoma Treated with First-Line Immunochemotherapy: A Review of PET/CT in Patients Who Did Not Achieve a Complete Metabolic Response in the GALLIUM Study. J Nucl Med. 2021. PMID: 34857656. doi:10.2967/jnumed.121.262869
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。